3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide has been researched along with guanylyl imidodiphosphate in 1 studies
Studies (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Trials (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Recent Studies (post-2010) (3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide) | Studies (guanylyl imidodiphosphate) | Trials (guanylyl imidodiphosphate) | Recent Studies (post-2010) (guanylyl imidodiphosphate) |
---|---|---|---|---|---|
14 | 0 | 6 | 2,356 | 1 | 18 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Johnson, RL; Mishra, RK; Srivastava, LK | 1 |
1 other study(ies) available for 3-(n-prolylamine)-2-oxo-1-pyrrolidineacetamide and guanylyl imidodiphosphate
Article | Year |
---|---|
Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide.
Topics: Animals; Binding, Competitive; Cattle; Cell Membrane; Corpus Striatum; Guanylyl Imidodiphosphate; Kinetics; MSH Release-Inhibiting Hormone; Pyrrolidinones; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone | 1990 |